Journal: RMD Open

Article Title: Peptide-based vaccine targeting IL17A attenuates experimental spondyloarthritis in HLA-B27 transgenic rats

doi: 10.1136/rmdopen-2022-002851

Figure Lengend Snippet: Interleukin (IL)−17A (IL17A) vaccine induces antibody production in a spondyloarthritis (SpA) model in human leucocyte antigen (HLA)-B27 transgenic rats. (A) Targeted sequences of IL17A vaccine are shown. (B) Experimental protocol for IL17A vaccination of the inactivated Mycobacterium Tuberculosis (MT)-induced SpA model in HLA-B27 transgenic rats. The epitope was conjugated with keyhole limpet hemocyanin (KLH). KLH-conjugated IL17A vaccine was injected with an alum adjuvant. HLA-B27 transgenic rats were immunised with the IL17A vaccine with KLH or KLH only intracutaneously thrice every 2 weeks. Inactivated MT was administrated to induced SpA. Blood was collected at 0, 2,4, 6 and 9 weeks to evaluate the antibody titre. Joint, tail and other tissues were collected at 9 weeks. The arthritis score and joint thickness were evaluated every few days. B.C.: blood collection. (C) Antibody titre for IL17A epitope. (D) Binding affinity of the vaccine-induced antibody for recombinant IL17A analysed via ELISA. Antibody of immunised serum at 9 weeks showed specific binding to recombinant IL17A, but not recombinant IL17F. (E) Antibody titre of IL17A epitope-specific IgG subclasses, IgG1 (Th2) and IgG2a (Th1). (F) The balance of Th1/Th2 was evaluated by the IgG2a/IgG1 ratio. IgG2a antibody titre was individually divided by the IgG1 antibody titre. See also .

Article Snippet: In that study, mice immunised with recombinant ovalbumin-conjugated mouse IL17A with Gerbu 100 adjuvant produced an IL17A-specific antibody, which suppressed IL17A bioactivity.

Techniques: Transgenic Assay, Injection, Adjuvant, Binding Assay, Recombinant, Enzyme-linked Immunosorbent Assay

Journal: RMD Open

Article Title: Peptide-based vaccine targeting IL17A attenuates experimental spondyloarthritis in HLA-B27 transgenic rats

doi: 10.1136/rmdopen-2022-002851

Figure Lengend Snippet: IL17A vaccine alleviates Mycobacterium tuberculosis (MT)-induced spondyloarthritis (SpA) in HLA-B27 transgenic rats. (A) Body weight was monitored after IL17A vaccination. (B) Arthritis score and (C) joint thickness were analysed every 2–3 d to determine the arthritis severity. Data are shown as the mean ± SE error of the mean (SEM). *p < 0.05 versus MT only, **p < 0.05 versus MT only, and KLH-control+MT, respectively.

Article Snippet: In that study, mice immunised with recombinant ovalbumin-conjugated mouse IL17A with Gerbu 100 adjuvant produced an IL17A-specific antibody, which suppressed IL17A bioactivity.

Techniques: Transgenic Assay, Control

Journal: RMD Open

Article Title: Peptide-based vaccine targeting IL17A attenuates experimental spondyloarthritis in HLA-B27 transgenic rats

doi: 10.1136/rmdopen-2022-002851

Figure Lengend Snippet: IL17A vaccine suppresses enthesitis and bone remodelling in the joints of HLA-B27 transgenic rats. (A) Representative pictures of spine and ankle. Arrows indicate swelling. (B) Immunohistological analysis (HE and CD68 staining) of the joint of spine and ankle. Circle indicates invasion of immune cells. (C) Immunohistological analysis (CD14 and alkaline phosphatase (ALP) staining) of the joint of spine and ankle at 9 weeks. See also .

Article Snippet: In that study, mice immunised with recombinant ovalbumin-conjugated mouse IL17A with Gerbu 100 adjuvant produced an IL17A-specific antibody, which suppressed IL17A bioactivity.

Techniques: Transgenic Assay, Staining

Journal: RMD Open

Article Title: Peptide-based vaccine targeting IL17A attenuates experimental spondyloarthritis in HLA-B27 transgenic rats

doi: 10.1136/rmdopen-2022-002851

Figure Lengend Snippet: IL17A peptide vaccine does not activate IL17A-specific T cell reaction. Representative images of (A) IL4 or (C) interferon (IFN)γ spots obtained via the enzyme-linked immunospot (ELISpot) assay. Splenocytes from immunised HLA-B27 transgenic rats were stimulated with recombinant IL17A, KLH or KLH-IL17 peptide (vaccine), or phorbol 12-myristate 13-acetate (PMA) plus ionomycin (IO) (PMA/IO) as a positive control. The graph shows the number of (B) IL4 or (D) IFNγ spots per 2 x 10 5 cells. Data are shown as the mean ± SEM. *p < 0.05 versus Control and IL17A, respectively.

Article Snippet: In that study, mice immunised with recombinant ovalbumin-conjugated mouse IL17A with Gerbu 100 adjuvant produced an IL17A-specific antibody, which suppressed IL17A bioactivity.

Techniques: Enzyme-linked Immunospot, Transgenic Assay, Recombinant, Positive Control, Control

Journal: RMD Open

Article Title: Peptide-based vaccine targeting IL17A attenuates experimental spondyloarthritis in HLA-B27 transgenic rats

doi: 10.1136/rmdopen-2022-002851

Figure Lengend Snippet: IL17A peptide vaccine does not mitigate MT-induced SpA in treatment model. (A) Experimental protocol for IL17A vaccination of MT-induced SpA treatment model in HLA-B27 transgenic rats. MT was administered to induce SpA at a week before administration of IL17A vaccine. IL17A vaccine or KLH control was administrated thrice at 2 weeks interval. Blood was collected at 1, 3, 5, 7 and 10 weeks to evaluate the antibody titre. The arthritis score and joint thickness were evaluated every few days. B.C.: blood collection. (B) Antibody titre for IL17A epitope. (C) Body weight was monitored after MT administration. (D) Arthritis score and (E) joint thickness were analysed every 2–3 days to determine the arthritis severity. Data are shown as the mean ± SE error of the mean (SEM). See also .

Article Snippet: In that study, mice immunised with recombinant ovalbumin-conjugated mouse IL17A with Gerbu 100 adjuvant produced an IL17A-specific antibody, which suppressed IL17A bioactivity.

Techniques: Transgenic Assay, Control